RESUMO
The Wilms' tumor gene WT1 is overexpressed in various kinds of hematopoietic malignancies as well as solid cancers, and this protein has been demonstrated to be an attractive target antigen for cancer immunotherapy. WT1-specific CTL epitopes with a restriction of HLA-A 2402 or HLA-A 0201 have been already identified. In the present study it has been demonstrated that a 9-mer WT1-derived WT1(187) peptide, which had already been shown to elicit a WT1-specific CTL response with a restriction of HLA-A 0201, can also elicit a CTL response with a restriction of HLA-A 0206. In all three different HLA-A 0206(+) healthy donors examined, WT1(187) peptide-specific CTL could be generated from peripheral blood mononuclear cells, and the CTL showed cytotoxic activity that depended on dual expression of WT1 and HLA-A 0206 molecules. The present study describes the first identification of a HLA-A 0206-restricted, WT1-specific CTL epitope. The present results should help to broaden the application of WT1 peptide-based immunotherapy from only HLA-A 0201-positive to HLA-A 0206-positive cancer patients as well.
Assuntos
Epitopos de Linfócito T/imunologia , Antígenos HLA-A/imunologia , Linfócitos T Citotóxicos/imunologia , Proteínas WT1/imunologia , Linfócitos T CD8-Positivos/imunologia , Linhagem Celular Tumoral , Testes Imunológicos de Citotoxicidade , Mapeamento de Epitopos , Genes do Tumor de Wilms , Antígeno HLA-A2 , Humanos , Oligopeptídeos/imunologiaRESUMO
OBJECTIVE: We investigated whether established graft-vs-host disease (GVHD) could be successfully treated by a second allogeneic bone marrow transplantation (BMT) through elimination of first donor-derived lymphocytes responsible for GVHD. MATERIALS AND METHODS: In a murine GVHD model of BDF1 (H-2(b/d))-->B6C3F1(H-2(b/k)), GVHD mice underwent a second BMT using a graft (1 x 10(7) bone marrow and 3 x 10(7) spleen cells) from a major histocompatibility complex (MHC) antigen haploidentically mismatched (to host and also to first donor) mouse strain, B6B10F1(H-2(b/s)), following low-dose total body irradiation (TBI) 2 to 3 weeks after the first BMT. RESULTS: Results demonstrated that severe GVHD could be successfully and stably treated by a second allogeneic BMT. For successful treatment of GVHD, rapid achievement of full second-donor T-cell chimerism was required. Furthermore, we showed that mice with GVHD could easily accept MHC haploidentically mismatched second-donor hematopoietic cells even after minimal conditioning (2-4 Gy TBI) because they were in a profoundly immunosuppressed state, and that the mice were relatively resistant to new development of GVHD by second-donor grafts. Furthermore, the timing of the second BMT, the intensity of conditioning treatment (GVHD mice are very sensitive), and donor selection were also found to be important for obtaining successful outcomes. Increased regulatory T cells and reduction of interferon-gamma levels may be involved in tolerance induction. CONCLUSIONS: We demonstrated that established GVHD in a murine GVHD model could be successfully treated by a second BMT from a third-party allogeneic donor.
Assuntos
Transplante de Medula Óssea , Doença Enxerto-Hospedeiro/cirurgia , Subpopulações de Linfócitos T/imunologia , Doadores de Tecidos , Animais , Feminino , Doença Enxerto-Hospedeiro/imunologia , Histocompatibilidade , Interferon gama/biossíntese , Interferon gama/genética , Camundongos , Camundongos Endogâmicos C3H , Camundongos Endogâmicos DBA , Quimera por Radiação , Reoperação , Subpopulações de Linfócitos T/transplante , Linfócitos T Reguladores/imunologia , Células Th1/imunologia , Células Th2/imunologia , Condicionamento Pré-Transplante , Tolerância ao Transplante , Transplante Homólogo , Fator de Necrose Tumoral alfa/biossíntese , Fator de Necrose Tumoral alfa/genéticaRESUMO
Effective tumor vaccine may be required to induce both cytotoxic T lymphocyte (CTL) and CD4+ helper T-cell responses against tumor-associated antigens. CD4+ helper T cells that recognize HLA class II-restricted epitopes play a central role in the initiation and maintenance of antitumor immune responses. The Wilms tumor gene WT1 is overexpressed in both leukemias and solid tumors, and the WT1 protein was demonstrated to be an attractive target antigen for cancer immunotherapy. In this study, we identified a WT1 protein-derived 16-mer peptide, WT1(332)(KRYFKLSHLQMHSRKH), which was restricted with HLA-DRB1*0405, one of the most common HLA class II types in Japanese, as a helper epitope that could elicit WT1-specific CD4+ T-cell responses. We established a WT1(332)-specific CD4+ helper T-cell clone (E04.1), which could respond to both HLA-DRB1*0405-positive, WT1-expressing transformed hematopoietic cells and autologous dendritic cells pulsed with apoptosis-induced WT1-expressing cells, indicating that the WT1(332) was a naturally processed helper epitope. Stimulation of peripheral blood mononuclear cells with both the CTL epitope (WT1(235)) and the helper epitope (WT1(332)) in the presence of WT1(332)-specific TH1-type CD4+ T cell clone strikingly enhanced the induction and the functional activity of WT1(235)-specific CTLs compared with that of peripheral blood mononuclear cells with the WT1(235) alone. These results indicated that a helper epitope, WT1(332) should be useful for improvement of the efficacy of CTL epitope-based cancer vaccine targeting WT1 in the clinical setting.
Assuntos
Epitopos de Linfócito T/imunologia , Epitopos de Linfócito T/farmacologia , Antígenos HLA-DR/imunologia , Oligopeptídeos/imunologia , Oligopeptídeos/farmacologia , Linfócitos T Citotóxicos/efeitos dos fármacos , Proteínas WT1/imunologia , Linfócitos T CD4-Positivos/efeitos dos fármacos , Linfócitos T CD4-Positivos/imunologia , Vacinas Anticâncer/imunologia , Mapeamento de Epitopos , Epitopos de Linfócito T/genética , Genes do Tumor de Wilms , Cadeias HLA-DRB1 , Humanos , Interferon gama , Ativação Linfocitária , Oligopeptídeos/genética , Linfócitos T Citotóxicos/imunologia , Proteínas WT1/química , Proteínas WT1/genéticaRESUMO
The major problems in human leukocyte antigen (HLA)-mismatched stem cell transplantation (SCT) are graft failure and graft-versus-host disease (GVHD). Less-intensive regimens should be associated with a lower release of inflammatory cytokines and possibly less GVHD. The objective of this study was to investigate whether HLA-haploidentical SCT can be performed using nonmyeloablative conditioning and pharmacologic GVHD prophylaxis, including glucocorticoids. Using conditioning consisting of fludarabine, busulfan, and anti-T-lymphocyte globulin and GVHD prophylaxis consisting of tacrolimus and methylprednisolone (1 mg/kg/day), 26 patients who had hematologic malignancies in an advanced stage or with a poor prognosis underwent transplantation using peripheral blood stem cells from an HLA-haploidentical donor (2-3 antigen mismatches in the graft-versus-host [GVH] direction) without T-cell depletion. All patients except for 1 achieved donor-type engraftment. Rapid hematologic engraftment was achieved (neutrophils > 0.5 x 10(9)/L on day 12 and platelets > 20 x 10(9)/L on day 12), with full donor chimerism achieved by day 14. Fifteen patients did not develop acute GVHD clinically, and only 5 patients developed grade II GVHD. The recovery of CD4+ T cells was delayed compared with that of CD8+ T cells. Sixteen of the 26 patients are alive in complete remission. Four died of transplantation-related causes, and 6 died of progressive disease. These data suggest that nonmyeloablative conditioning, GVHD prophylaxis consisting of tacrolimus and methylprednisolone, and early therapeutic intervention for the GVH reaction allow stable engraftment and effectively suppress GVHD in HLA 2-3 antigen-mismatched SCT.
Assuntos
Doença Enxerto-Hospedeiro/prevenção & controle , Antígenos HLA/análise , Neoplasias Hematológicas/cirurgia , Histocompatibilidade , Transplante de Células-Tronco de Sangue Periférico/estatística & dados numéricos , Condicionamento Pré-Transplante , Transplante Homólogo/imunologia , Adulto , Soro Antilinfocitário/administração & dosagem , Medula Óssea/efeitos dos fármacos , Medula Óssea/imunologia , Medula Óssea/efeitos da radiação , Bussulfano/administração & dosagem , Contagem de Linfócito CD4 , Terapia Combinada , Citocinas/fisiologia , Intervalo Livre de Doença , Família , Feminino , Sobrevivência de Enxerto , Doença Enxerto-Hospedeiro/epidemiologia , Doença Enxerto-Hospedeiro/etiologia , Antígenos HLA/genética , Neoplasias Hematológicas/tratamento farmacológico , Neoplasias Hematológicas/mortalidade , Humanos , Imunossupressores/uso terapêutico , Incidência , Masculino , Metilprednisolona/uso terapêutico , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/tratamento farmacológico , Síndromes Mielodisplásicas/mortalidade , Síndromes Mielodisplásicas/cirurgia , Transplante de Células-Tronco de Sangue Periférico/mortalidade , Recidiva , Indução de Remissão , Linfócitos T , Tacrolimo/uso terapêutico , Doadores de Tecidos , Condicionamento Pré-Transplante/mortalidade , Resultado do Tratamento , Vidarabina/administração & dosagem , Vidarabina/análogos & derivadosRESUMO
It is well known that the Wilms' tumor gene WT1 plays an important role in cell proliferation and differentiation, and in organ development. In this study, to examine the role of the WT1 gene in lineage determination, fetal liver cells from LacZ-transgenic mice, in which WT1 expression was marked by the expression of the LacZ gene driven by WT1 promoter, were FACS-sorted according to LacZ expression of high (LacZ(++)) or undetectable (LacZ(-)) levels, which paralleled endogenous WT1 expression levels. LacZ(++) fetal liver cells were enriched by hepatocyte and endothelial progenitor cells. These results indicated that WT1 expression is a common marker of both hepatocyte and endothelial progenitors. These results also implied a role of the WT1 gene in lineage determination.
Assuntos
Genes do Tumor de Wilms , Marcadores Genéticos/genética , Fígado/embriologia , Fígado/metabolismo , Células-Tronco/metabolismo , Proteínas WT1/genética , Proteínas WT1/metabolismo , Animais , Células Cultivadas , Regulação da Expressão Gênica no Desenvolvimento/fisiologia , Testes Genéticos/métodos , Hepatócitos/classificação , Hepatócitos/citologia , Hepatócitos/metabolismo , Fígado/citologia , Camundongos , Camundongos Transgênicos , Células-Tronco/classificação , Células-Tronco/citologia , beta-Galactosidase/genética , beta-Galactosidase/metabolismoAssuntos
Apresentação de Antígeno/imunologia , Epitopos de Linfócito T/imunologia , Antígenos HLA-A/imunologia , Oligopeptídeos/imunologia , Linfócitos T Citotóxicos/imunologia , Proteínas WT1/imunologia , Vacinas Anticâncer/imunologia , Antígeno HLA-A2 , Neoplasias Hematológicas/imunologia , Neoplasias Hematológicas/terapia , Humanos , Células K562 , Vacinação/métodosRESUMO
The Wilms' tumor gene WT1 is overexpressed in leukemias and various types of solid tumors, and the WT1 protein was demonstrated to be an attractive target antigen for immunotherapy against these malignancies. Here, we report the outcome of a phase I clinical study of WT1 peptide-based immunotherapy for patients with breast or lung cancer, myelodysplastic syndrome, or acute myeloid leukemia. Patients were intradermally injected with an HLA-A*2402-restricted, natural, or modified 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant at 0.3, 1.0, or 3.0 mg per body at 2-week intervals, with toxicity and clinical and immunological responses as the principal endpoints. Twenty-six patients received one or more WT1 vaccinations, and 18 of the 26 patients completed WT1 vaccination protocol with three or more injections of WT1 peptides. Toxicity consisted only of local erythema at the WT1 vaccine injection sites in patients with breast or lung cancer or acute myeloid leukemia with adequate normal hematopoiesis, whereas severe leukocytopenia occurred in patients with myelodysplastic syndrome with abnormal hematopoiesis derived from WT1-expressing, transformed hematopoietic stem cells. Twelve of the 20 patients for whom the efficacy of WT1 vaccination could be assessed showed clinical responses such as reduction in leukemic blast cells or tumor sizes and/or tumor markers. A clear correlation was observed between an increase in the frequencies of WT1-specific cytotoxic T lymphocytes after WT1 vaccination and clinical responses. It was therefore demonstrated that WT1 vaccination could induce WT1-specific cytotoxic T lymphocytes and result in cancer regression without damage to normal tissues.
Assuntos
Vacinas Anticâncer/toxicidade , Neoplasias/imunologia , Linfócitos T Citotóxicos/imunologia , Proteínas WT1/imunologia , Substituição de Aminoácidos , Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/imunologia , Neoplasias da Mama/patologia , Feminino , Regulação Neoplásica da Expressão Gênica/imunologia , Genes do Tumor de Wilms , Humanos , Japão , Neoplasias Renais/imunologia , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/imunologia , Radiografia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Proteínas WT1/genética , Tumor de Wilms/imunologiaAssuntos
Efeito Enxerto vs Leucemia/fisiologia , Antígenos HLA/imunologia , Leucemia/terapia , Transplante de Células-Tronco/efeitos adversos , Evolução Fatal , Doença Enxerto-Hospedeiro/tratamento farmacológico , Haplótipos , Teste de Histocompatibilidade , Humanos , Imunossupressores/uso terapêutico , Leucemia/imunologia , Depleção Linfocítica , Masculino , Linfócitos T/imunologiaRESUMO
A Wilms' tumor gene WT1 is expressed at high levels not only in most types of leukemia but also in various types of solid tumors, including lung and breast cancer. WT1 protein has been reported to serve as a target antigen for tumor-specific immunotherapy both in vitro in human systems and in vivo in murine models. We have shown that mice immunized with WT1 peptide or WT1 cDNA could reject a challenge from WT1-expressing tumor cells (a "prophylactic" model). However, it was not examined whether WT1 peptide vaccination had the potency to reject tumor cells in a "therapeutic" setting. In the present study, we demonstrated for the first time that WT1 peptide vaccination combined with Mycobacterium bovis bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) was more effective for eradication of WT1-expressing tumor cells that had been implanted into mice before vaccination (a "therapeutic" model) compared with WT1 peptide vaccination alone. An intradermal injection of BCG-CWS into mice, followed by that of WT1 peptide at the same site on the next day, generated WT1-specific cytotoxic T lymphocytes (CTLs) and led to rejection of WT1-expressing leukemia or lung cancer cells. These results showed that BCG-CWS, which was well known to enhance innate immunity, could enhance WT1-specific immune responses (acquired immunity) in combination with WT1 peptide vaccination. Therefore, WT1 peptide vaccination combined with BCG-CWS may be applied to cancer immunotherapy in clinical settings.
Assuntos
Vacinas Anticâncer/uso terapêutico , Leucemia/terapia , Lipopolissacarídeos/imunologia , Neoplasias Pulmonares/terapia , Fragmentos de Peptídeos/imunologia , Vacinação , Proteínas WT1/imunologia , Animais , Medula Óssea/imunologia , Medula Óssea/metabolismo , Medula Óssea/patologia , Ensaio de Unidades Formadoras de Colônias , Imunoterapia , Rim/imunologia , Rim/metabolismo , Rim/patologia , Leucemia/metabolismo , Neoplasias Pulmonares/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Fragmentos de Peptídeos/uso terapêutico , Linfócitos T Citotóxicos/imunologia , Células Tumorais Cultivadas/transplante , Proteínas WT1/uso terapêuticoRESUMO
The Wilms' tumor gene WT1 is overexpressed in various types of solid tumors, including lung and breast cancer and WT1 protein is a tumor antigen for these malignancies. In phase I clinical trials of WT1 peptide-based cancer immunotherapy, two patients with advanced lung cancer were intradermally injected with 0.3 mg of an HLA-A*2402-restricted, 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant. Consecutive WT1 vaccination at 2-week intervals resulted in a reduction in tumor markers such as chorio-embryonic antigen (CEA) and sialyl Lewis (x) (SLX) and by a transient decrease in tumor size. No adverse effects except for local erythema at the injection sites of WT1 vaccine were observed. These results provided us with the first clinical evidence demonstrating that WT1 peptide-based immunotherapy should be a promising treatment for patients with lung cancer.
Assuntos
Antígenos de Neoplasias/administração & dosagem , Vacinas Anticâncer/genética , Vacinas Anticâncer/imunologia , Imunoterapia/métodos , Neoplasias Pulmonares/terapia , Proteínas WT1/administração & dosagem , Idoso , Antígenos de Neoplasias/uso terapêutico , Vacinas Anticâncer/efeitos adversos , Vacinas Anticâncer/uso terapêutico , Sistemas de Liberação de Medicamentos/efeitos adversos , Sistemas de Liberação de Medicamentos/métodos , Feminino , Antígenos HLA-A/administração & dosagem , Antígenos HLA-A/uso terapêutico , Humanos , Neoplasias Pulmonares/etiologia , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Fragmentos de Peptídeos/administração & dosagem , Fragmentos de Peptídeos/imunologia , Fragmentos de Peptídeos/uso terapêutico , Resultado do Tratamento , Proteínas WT1/imunologia , Proteínas WT1/uso terapêuticoRESUMO
We present the case of a patient with myelodysplastic syndrome who experienced leukemia transformation and subsequently underwent transplantation of unmanipulated peripheral blood stem cells from a haploidentical sibling mismatched at 3 HLA antigens, along with a reduced-intensity regimen (fludarabine, busulfan, and anti-T-lymphocyte globulin) and tacrolimus-containing graft-versus-host disease (GVHD) prophylaxis. The patient experienced graft rejection but successfully underwent a second transplantation from the same donor with a slightly intensified conditioning regimen. Although the patient developed life-threatening cytomegalovirus (CMV) pneumonia following the second transplantation, he recovered completely from the pneumonia with intensive supportive therapy. He is still in complete remission past day 1000 in the absence of GVHD. As far as we know, this report is the first to describe a successful second transplantation that was performed for graft rejection following HLA-haploidentical nonmyeloablative stem cell transplantation. Furthermore, we emphasize that patients should be carefully monitored for CMV infection when reduced-intensity conditioning is given repeatedly over a short period.
Assuntos
Rejeição de Enxerto , Antígenos HLA , Haploidia , Transplante de Células-Tronco Hematopoéticas , Histocompatibilidade , Síndromes Mielodisplásicas/terapia , Adulto , Transformação Celular Neoplásica , Rejeição de Enxerto/imunologia , Doença Enxerto-Hospedeiro/tratamento farmacológico , Doença Enxerto-Hospedeiro/imunologia , Antígenos HLA/imunologia , Histocompatibilidade/imunologia , Teste de Histocompatibilidade , Humanos , Imunossupressores/administração & dosagem , Masculino , Indução de RemissãoRESUMO
We previously showed that Wilms tumor gene (WT1) expression level, measured by quantitative reverse transcriptase polymerase chain reaction (RT-PCR), was useful as an indicator of minimal residual disease (MRD) in leukemia and myelodysplastic syndrome. However, in conventional quantitative RT-PCR (CQ-PCR), RT-PCR must be performed for various numbers of cycles depending on WT1 expression level. In the present study, we developed a new real-time quantitative RT-PCR (RQ-PCR) method for quantitating WT1 transcripts. Results of intraassay and interassay variability tests demonstrated that the real-time WT1 assay had high reproducibility. WT1 expression levels measured by the RQ- and the CQ-PCR methods were strongly correlated (r = 0.998). Furthermore, a strong correlation was observed among WT1 transcript values normalized with 3 different control genes (beta-actin, ABL, and glyceraldehyde-3-phosphate dehydrogenase) and between relative WT1 transcript values with WT1 expression in K562 cells as the reference and absolute WT1 transcript copy numbers per microgram RNA. When WT1 expression and minor bcr-abl expression were concurrently monitored in 2 patients with bcr-abl-positive acute lymphoblastic leukemia, both MRDs changed mostly in parallel, indicating the reliability and validity of our RQ-PCR method. In conclusion, this RQ-PCR method is convenient and reliable for monitoring MRD and enables routine clinical use of a WT1 assay.
Assuntos
Genes do Tumor de Wilms , Leucemia/diagnóstico , Técnicas de Diagnóstico Molecular/métodos , Neoplasia Residual/diagnóstico , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Dosagem de Genes , Humanos , Células K562 , Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico , RNA Mensageiro/análise , Reprodutibilidade dos TestesRESUMO
The Wilms tumor gene, WT1, is overexpressed not only in leukemias and myelodysplastic syndrome (MDS) but also in various types of solid tumors, including lung and breast cancer, and the WT1 protein is a tumor antigen for these malignancies. In clinical trials of WT1 peptide-based cancer immunotherapy, patients with overt leukemia from MDS or MDS with myelofibrosis were injected intradermally with 0.3 mg of an HLA-A*2402-restricted, 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant. Only a single dose of WT1 vaccination resulted in an increase in WT1-specific cytotoxic T-lymphocytes, which was followed by a rapid reduction in leukemic blast cells. Severe leukopenia and local erythema at the injection sites of WT1 peptide were observed as adverse effects. These results have provided us with the first clinical evidence suggesting that WT1 peptide-based immunotherapy is an attractive treatment for patients with leukemias or MDS.
Assuntos
Antígenos de Neoplasias/administração & dosagem , Imunoterapia/métodos , Leucemia/terapia , Síndromes Mielodisplásicas/patologia , Proteínas WT1/imunologia , Idoso , Antígenos de Neoplasias/uso terapêutico , Feminino , Antígenos HLA-A/administração & dosagem , Antígenos HLA-A/uso terapêutico , Humanos , Leucemia/etiologia , Leucemia/patologia , Masculino , Pessoa de Meia-Idade , Fragmentos de Peptídeos/administração & dosagem , Fragmentos de Peptídeos/imunologia , Fragmentos de Peptídeos/uso terapêutico , Mielofibrose Primária/patologia , Resultado do Tratamento , VacinaçãoRESUMO
In the thymi of WT1-transgenic (Tg) mice with the 17AA+/KTS- spliced form of the Wilms tumor gene WT1 driven by the lck promoter, the frequencies of CD4-CD8- double-negative (DN) thymocytes were significantly increased relative to those in normal littermates. Of the 4 subsets of CD4-CD8- DN thymocytes, the DN1 (CD44+CD25-) subset increased in both frequency and absolute cell number, whereas the DN2 (CD44+CD25+) and DN3 (CD44-CD25+) subsets decreased, indicating the blocking of thymocyte differentiation from the DN1 to the DN2 subsets. Furthermore, CD4-CD8+ T-cell receptor (TCR) -gammadelta T-cells increased in both frequency and absolute cell number in the spleen and peripheral blood of the WT1-Tg mice relative to those of normal littermates. The CD8 molecules of these CD4-CD8+ TCRgammadelta T-cells were CD8alphabeta, suggesting that they originated from the thymus. These results are the first direct evidence demonstrating that the WT1 gene is involved in the development and differentiation of T-lineage cells.
Assuntos
Proteína Tirosina Quinase p56(lck) Linfócito-Específica/genética , Regiões Promotoras Genéticas , Linfócitos T/citologia , Timo/citologia , Proteínas WT1/fisiologia , Animais , Antígenos CD/análise , Antígenos CD8/análise , Linfócitos T CD8-Positivos/citologia , Contagem de Células , Diferenciação Celular , Camundongos , Camundongos Transgênicos , Receptores de Antígenos de Linfócitos T gama-delta , Subpopulações de Linfócitos T/citologia , Proteínas WT1/genéticaRESUMO
Activation-induced cell death (AICD) of lymphocytes is an apoptotic pathway involved in the control of T-cell homeostasis. The magnitude of graft-vs.-host disease (GVHD) following allogeneic hematopoietic cell transplantation may be attenuated by the enhancement of AICD. The aim of the present study was to clarify the effect of T cell dose upon the fate (proliferation or apoptosis) of individual activated T cells in a murine GVHD model. To this end, we investigated the kinetics of the proliferation and apoptosis of donor T cells in recipient spleens in the early stage of a fully major histocompatibility complex (MHC)-mismatched murine transplantation model from C57BL/6 (H-2(b)) to lethally-irradiated (8.5 Gy) BALB/c (H-2(d)) mice. To track the behavior of alloreactive lymphocytes in vivo, we used the fluorescent cytoplasmic dye carboxyfluorescein diacetate succinimidyl ester in combination with flow cytometry. Engraftment of donor T cells to recipient spleens was almost completed within 24 h after transfer. After that, at higher doses of transferred cells, the donor T cells actively divided for up to 72 h resulting in a 30-fold increase in cell number at the maximum cell dose (2.0 x 10(7)). As the transferred cell dose decreased, the proliferation of T cells tended to be suppressed. At cell doses of 0.5 x 10(7) or less, the proliferation of T cells was profoundly suppressed, ultimately resulting in little proliferation of donor T cells observed from 24 to 72 h at the minimum cell dose (0.1 x 10(7)). The frequency of Annexin-V-positive cells was found to increase gradually as the transferred cell dose decreased. Thus, an increase in apoptotic events appeared to play an important role in the suppression of the proliferation of T cells at lower splenocyte doses. Further analyses revealed that Fas ligand (FasL)-positive T cells were observed exclusively among T cells that divided at least 5 times, and that all of them were positive for Annexin-V, indicating that they were in the process of apoptosis. Together with our finding that the frequency of apoptosis increased with the progression of cell division, these findings strongly suggest that AICD occurred through the Fas/FasL system and that AICD increased as the dose of donor T cells participating in the allogeneic response decreased. When relatively small numbers of T cells are confronted with an excess of antigen, they disappear. This process is called clonal exhaustion-deletion. Our results support the idea that AICD is involved in the process of clonal exhaustion-deletion. Relevant to the clinical aspects of hematopoietic cell transplantation, our findings indicate that AICD may be associated with tolerance induction in T-cell-depleted transplantation from HLA-mismatched donors, in which T cells contaminating marrow grafts do not need to be completely removed for achieving tolerance between donors and recipients. Furthermore, our results indicate that a small change in the quantitative balance between antigens and T cells responding to them leads to a large difference in the fate of T cells activated in response to MHC-incompatible antigens. Thus, the size of the T cell dose is one of the important considerations in tolerance induction, GVHD and rejection.
Assuntos
Apoptose/imunologia , Doença Enxerto-Hospedeiro/imunologia , Transplante de Células-Tronco Hematopoéticas , Complexo Principal de Histocompatibilidade/genética , Linfócitos T/imunologia , Transferência Adotiva/métodos , Animais , Anexina A5/metabolismo , Divisão Celular , Modelos Animais de Doenças , Feminino , Citometria de Fluxo , Transplante de Células-Tronco Hematopoéticas/métodos , Complexo Principal de Histocompatibilidade/imunologia , Camundongos , Linfócitos T/metabolismoRESUMO
In acute-type leukemia, no method for the prediction of relapse following allogeneic stem cell transplantation based on minimal residual disease (MRD) levels is established yet. In the present study, MRD in 72 cases of allogeneic transplantation for acute myeloid leukemia, acute lymphoid leukemia, and chronic myeloid leukemia (accelerated phase or blast crisis) was monitored frequently by quantitating the transcript of WT1 gene, a "panleukemic MRD marker," using reverse transcriptase-polymerase chain reaction. Based on the negativity of expression of chimeric genes, the background level of WT1 transcripts in bone marrow following allogeneic transplantation was significantly decreased compared with the level in healthy volunteers. The probability of relapse occurring within 40 days significantly increased step-by-step according to the increase in WT1 expression level (100% for 1.0 x 10(-2)-5.0 x 10(-2), 44.4% for 4.0 x 10(-3)-1.0 x 10(-2), 10.2% for 4.0 x 10(-4)-4.0 x 10(-3), and 0.8% for < 4.0 x 10(-4)) when WT1 level in K562 was defined as 1.0). WT1 levels in patients having relapse increased exponentially with a constant doubling time. The doubling time of the WT1 level in patients for whom the discontinuation of immunosuppressive agents or donor leukocyte infusion was effective was significantly longer than that for patients in whom it was not (P <.05). No patients with a short doubling time of WT1 transcripts (< 13 days) responded to these immunomodulation therapies. These findings strongly suggest that the WT1 assay is very useful for the prediction and management of relapse following allogeneic stem cell transplantation regardless of the presence of chimeric gene markers.
Assuntos
Regulação Leucêmica da Expressão Gênica , Genes do Tumor de Wilms , Leucemia/terapia , Proteínas de Neoplasias/genética , Transplante de Células-Tronco de Sangue Periférico , RNA Mensageiro/biossíntese , RNA Neoplásico/biossíntese , Doença Aguda , Crise Blástica/sangue , Crise Blástica/genética , Crise Blástica/patologia , Crise Blástica/terapia , Humanos , Células K562/metabolismo , Leucemia/sangue , Leucemia/genética , Leucemia/patologia , Leucemia Mieloide de Fase Acelerada/sangue , Leucemia Mieloide de Fase Acelerada/genética , Leucemia Mieloide de Fase Acelerada/patologia , Leucemia Mieloide de Fase Acelerada/terapia , Proteínas de Neoplasias/biossíntese , Neoplasia Residual/diagnóstico , Valor Preditivo dos Testes , Recidiva , Estudos Retrospectivos , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transcrição Gênica , Transplante Homólogo , Resultado do Tratamento , Proteínas WT1/biossínteseRESUMO
The Wilms' tumor gene WT1 is overexpressed in most types of leukemias and various kinds of solid tumors, including lung and breast cancer, and participates in leukemogenesis and tumorigenesis. WT1 protein has been reported to be a promising tumor antigen in mouse and human. In the present study, a single amino-acid substitution, M-->Y, was introduced into the first anchor motif at position 2 of the natural immunogenic HLA-A*2402-restricted 9-mer WT1 peptide (CMTWNQMNL; a.a. 235-243). This substitution increased the binding affinity of the 9-mer WT1 peptide to HLA-A*2402 molecules from 1.82 x 10(-5) to 6.40 x 10(-7) M. As expected from the increased binding affinity, the modified 9-mer WT1 peptide (CYTWNQMNL) elicited WT1-specific cytotoxic T lymphocytes (CTL) more effectively than the natural 9-mer WT1 peptide from peripheral blood mononuclear cells (PBMC) of HLA-A*2402-positive healthy volunteers. CTL induced by the modified 9-mer WT1 peptide killed the natural 9-mer WT1 peptide-pulsed CIR-A*2402 cells, primary leukemia cells with endogenous WT1 expression and lung cancer cell lines in a WT1-specific HLA-A*2402-restricted manner. These results showed that this modified 9-mer WT1 peptide was more immunogenic for the induction of WT1-specific CTL than the natural 9-mer WT1 peptide, and that CTL induced by the modified 9-mer WT1 peptide could effectively recognize and kill tumor cells with endogenous WT1 expression. Therefore, cancer immunotherapy using this modified 9-mer WT1 peptide should provide efficacious treatment for HLA-A*2402-positive patients with leukemias and solid tumors.
Assuntos
Antígenos HLA-A/metabolismo , Neoplasias/terapia , Fragmentos de Peptídeos/imunologia , Linfócitos T Citotóxicos/imunologia , Proteínas WT1/imunologia , Humanos , Imunoterapia , Células Tumorais Cultivadas , Proteínas WT1/genética , Proteínas WT1/metabolismoRESUMO
The Wilms' tumour gene, WT1, is expressed at high levels in leukaemia cells and plays an important role in leukaemogenesis. WT1 is also expressed in human normal CD34+ bone marrow (BM) cells at about 100 times lower levels than in leukaemia cells. To identify and characterize WT1-expressing cells in CD34+ BM cells, they were sorted into single cells and analysed for WT1 expression using two kinds of single-cell reverse transcriptase polymerase chain reaction (RT-PCR) methods. Using the semiquantitative single-cell polyA-PCR + sequence-specific (SS)-PCR method, WT1 expression was detected in four (1.3%) out of 319 CD34+ BM single cells. To confirm the above results, a single-cell nested sequence-specific (NSS)-RT-PCR method that was less quantitative but more sensitive than the polyA-PCR + SS-PCR method was also performed, and WT1 expression was detected in 15 (1.1%) out of 1315 CD34+ BM single cells. In total, WT1 expression was found in 19 (1.2%) out of 1634 CD34+ BM single cells. No significant differences in the frequencies of WT1-expressing cells were found between CD34+CD38- and CD34+CD38+ BM single cells. Furthermore, WT1-expressing CD34+ BM single cells expressed WT1 at levels similar to those in K562 leukaemia single cells. Analysis of lineage-specific and cell cycle gene expression in WT1-expressing CD34+ BM single cells showed that the WT1 gene could be expressed in both uncommitted, dormant CD34+CD38- and lineage-committed, proliferating CD34+CD38+ BM cells. Our results could indicate that these WT1-expressing CD34+ BM cells were normal counterparts of leukaemia cells.